Regeneron Pharmaceuticals Inc (REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Industry: Pharmaceutical Preparations (SIC 2834)

Market region: US

Address: 777 Old Saw Mill River Road, Tarrytown, NY, 10591

Market capitalization

95.99 billion USD (95,988,233,888 USD)

Listing date

04/02/1991

Weighted shares outstanding

103,447,859

Share class shares outstanding

101,137,842

https://www.regeneron.com